Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinrebafusp alfa in HER2-expressing Gastric or GEJ Adenocarcinoma
NCT05190445Phase 2Active, not recruiting
- Sponsor
- Pieris Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of cinrebafusp alfa in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Pieris Pharmaceuticals. Started Nov 2021; status: active, not recruiting.
02
Drugs
cinrebafusp alfa
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05190445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05190445.